Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Lithium cation
Drug ID BADD_D01304
Description Lithium was used during the 19th century to treat gout. Lithium salts such as lithium carbonate (Li2CO3), lithium citrate, and lithium orotate are mood stabilizers. They are used in the treatment of bipolar disorder, since unlike most other mood altering drugs, they counteract both mania and depression. Lithium can also be used to augment other antidepressant drugs. It is also sometimes prescribed as a preventive treatment for migraine disease and cluster headaches. The active principle in these salts is the lithium ion Li+, which having a smaller diameter, can easily displace K+ and Na+ and even Ca+2, in spite of its greater charge, occupying their sites in several critical neuronal enzymes and neurotransmitter receptors.
Indications and Usage Lithium, in its salt forms, is used as a mood stabilizer and for the treatment of depression and mania. It is most frequently prescribed in the treatment of bipolar disorder.
Marketing Status experimental
ATC Code N05AN01
DrugBank ID DB01356
KEGG ID D08133
MeSH ID D008094
PubChem ID 28486
TTD Drug ID D5MF8Y
NDC Product Code Not Available
UNII 8H8Z5UER66
Synonyms Lithium | Lithium-7 | Lithium 7
Chemical Information
Molecular Formula Li+
CAS Registry Number 17341-24-1
SMILES [Li+]
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Thinking abnormal19.10.03.001; 17.02.05.0230.000192%Not Available
Thirst14.03.02.007; 08.01.09.0210.000518%Not Available
Thyroid disorder05.02.01.0020.000192%Not Available
Thyroiditis05.02.04.0010.000384%Not Available
Thyrotoxic crisis19.07.03.006; 14.11.01.016; 06.09.04.004; 05.02.02.0040.000576%Not Available
Tinnitus17.04.07.004; 04.04.01.002--
Tremor17.01.06.0020.009447%
Unresponsive to stimuli17.02.05.0310.000480%Not Available
Urinary incontinence20.02.02.010; 17.05.01.0080.000288%
Vertigo17.02.12.002; 04.04.01.003--
Vision blurred17.17.01.010; 06.02.06.007--
Visual field defect17.17.01.001; 06.02.07.003--Not Available
Vomiting07.01.07.0030.003437%
Water intoxication19.07.03.004; 14.05.06.004; 05.03.03.0030.000288%Not Available
Weight decreased13.15.01.005--
Weight increased13.15.01.006--
Wheezing22.03.01.0090.000422%
Mental status changes19.07.01.0010.002112%Not Available
Tubulointerstitial nephritis20.05.02.0020.001632%Not Available
Paradoxical drug reaction08.06.01.0140.000192%Not Available
Brain oedema17.07.02.003; 12.01.10.0100.000192%
Brain death17.02.03.003; 08.04.01.0040.000192%Not Available
Left ventricular dysfunction02.04.02.0110.000288%
Balance disorder17.02.02.007; 08.01.03.0810.000672%Not Available
Bradyphrenia19.10.03.002; 17.03.03.0040.000384%Not Available
Neonatal hypoxia22.11.02.002; 18.04.15.0020.000192%Not Available
Self-injurious ideation19.12.01.0070.000192%Not Available
Haemodynamic instability24.03.02.0060.000480%Not Available
Eosinophilic pustular folliculitis01.02.04.012; 23.03.03.0510.000192%Not Available
Musculoskeletal stiffness15.03.05.0270.000288%Not Available
The 8th Page    First    Pre   8 9 10 11    Next   Last    Total 11 Pages